Books and Book Chapters

    Experimental Models of Environmental Tobacco Smoke Exposure: Structural and Functional Changes in Epithelial Cells of the Respiratory Tract

    Schlage, W. K.; Teredesai, A.
    Date published
    Jun 15, 2000
    DOI
    10.1201/9781420042245
    ISBN
    9780429124587
    Published in
    Environmental Tobacco Smoke 
    Editors
    Witten, M. L.
    Link to publication
    Topic
    Summary

    The health effects of exposure to environmental tobacco smoke (ETS) have been the subject of numerous literature reviews during the past decade. Most of the investigations, which concluded that exposure to ETS may increase the risk of lung cancer, chronic obstructive pulmonary disease (COPD), cardiovascular disease, intrauterine growth retardation, and Sudden Infant Death Syndrome, are based on epidemiological studies (cf. References 1 to 6). In a notice of proposed rulemaking (NPR), the Occupational Safety and Health Administration (OSHA) concluded that ETS “may produce mucous membrane irritation, pulmonary, cardiovascular, reproductive and carcinogenic effects” and that ETS “presents a serious health risk to workers.”

    Related Publications

    A comparative assessment of HPHC yields and in vitro toxicity for 1R6F reference cigarette smoke versus aerosol generated by Tobacco Heating System 3.0

    Pre-clinical Toxicology

    Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated apolipoprotein E-deficient mice

    Pre-clinical Toxicology

    Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

    Pre-clinical Toxicology

    Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

    Pre-clinical Toxicology

    Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

    Pre-clinical Toxicology

    Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

    Pre-clinical Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.